Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2007 3
2008 3
2009 5
2010 3
2011 2
2012 2
2016 1
2018 1
2019 2
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Platinum pathway.
Marsh S, McLeod H, Dolan E, Shukla SJ, Rabik CA, Gong L, Hernandez-Boussard T, Lou XJ, Klein TE, Altman RB. Marsh S, et al. Among authors: shukla sj. Pharmacogenet Genomics. 2009 Jul;19(7):563-4. doi: 10.1097/FPC.0b013e32832e0ed7. Pharmacogenet Genomics. 2009. PMID: 19525887 Free PMC article. No abstract available.
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.
Yasinskaya Y, Bala S, Waack U, Dixon C, Higgins K, Moore JN, Jjingo CJ, O'Shaughnessy E, Colangelo P, Botgros R, Nambiar S, Angulo D, Dane A, Chiller T, Hodges MR, Sandison T, Hope W, Walsh TJ, Pappas P, Katragkou A, Kovanda L, Rex JH, Marr KA, Ostrosky-Zeichner L, Sekine S, Deshpande M, Shukla SJ, Farley J. Yasinskaya Y, et al. Among authors: shukla sj. Clin Infect Dis. 2023 Aug 14;77(3):380-387. doi: 10.1093/cid/ciad195. Clin Infect Dis. 2023. PMID: 37021650
FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.
O'Shaughnessy E, Yasinskaya Y, Dixon C, Higgins K, Moore J, Reynolds K, Ampel NM, Angulo D, Blair JE, Catanzaro A, Galgiani JN, Garvey E, Johnson R, Larwood DJ, Lewis G, Purdie R, Rex JH, Shubitz LF, Stevens DA, Page SJ, Shukla SJ, Farley JJ, Nambiar S. O'Shaughnessy E, et al. Among authors: shukla sj. Clin Infect Dis. 2022 Jun 10;74(11):2061-2066. doi: 10.1093/cid/ciab904. Clin Infect Dis. 2022. PMID: 34651656
FDA Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development.
Jjingo CJ, Bala S, Waack U, Needles M, Bensman TJ, McMaster O, Smith T, Blakely B, Chan IZ, Puthawala K, Dixon C, Kim Y, Lim R, Colangelo P, St Clair C, Nambiar S, Moss RB, Botgros R, Bazaz R, Denning DW, Marr KA, Husain S, Berman L, Christensen DJ, Keywood C, Clayton RG, Walsh TJ, Song HSE, Shukla SJ, Farley JJ. Jjingo CJ, et al. Among authors: shukla sj. Clin Infect Dis. 2023 Oct 6:ciad607. doi: 10.1093/cid/ciad607. Online ahead of print. Clin Infect Dis. 2023. PMID: 37802928
A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination.
Behrends CN, Eggman AA, Gutkind S, Bresnahan MP, Fluegge K, Laraque F, Litwin AH, Meissner P, Shukla SJ, Perumalswami PV, Weiss J, Wyatt BE, Schackman BR. Behrends CN, et al. Among authors: shukla sj. J Public Health Manag Pract. 2019 May/Jun;25(3):253-261. doi: 10.1097/PHH.0000000000000806. J Public Health Manag Pract. 2019. PMID: 29975342 Free PMC article.
Regulatory Considerations in the Approval of Rezafungin (REZZAYO) for the Treatment of Candidemia and Invasive Candidiasis in Adults.
Smith HL, Bensman TJ, Mishra S, Li X, Dixon CA, Sheikh J, McMaster OG, Joshi A, Rubin DB, Goodwin A, Miller TJ, Danielsen ZY, Syed I, Shukla SJ, Iarikov D, Kim PW, Farley JJ. Smith HL, et al. Among authors: shukla sj. J Infect Dis. 2024 Mar 19:jiae146. doi: 10.1093/infdis/jiae146. Online ahead of print. J Infect Dis. 2024. PMID: 38502709
26 results